Hodgkin lymphoma: A 2020 update on diagnosis, risk-stratification, and management.
Stephen M AnsellPublished in: American journal of hematology (2020)
High-dose chemotherapy (HDCT) followed by an autologous stem cell transplant (ASCT) is the standard of care for most patients who relapse following initial therapy. For patients who fail HDCT with ASCT, brentuximab vedotin, PD-1 blockade, non-myeloablative allogeneic transplant or participation in a clinical trial should be considered.
Keyphrases
- hodgkin lymphoma
- stem cell transplantation
- high dose
- stem cells
- clinical trial
- low dose
- bone marrow
- healthcare
- palliative care
- cell therapy
- locally advanced
- quality improvement
- open label
- study protocol
- pain management
- radiation therapy
- free survival
- double blind
- randomized controlled trial
- affordable care act
- mesenchymal stem cells
- rectal cancer
- acute myeloid leukemia